A global leader in pharmaceutical, biotech, and specialty ingredients manufacturing, Lonza provides contract development and production services for the healthcare industry. Investors monitor its performance due to its critical role in drug manufacturing and strong position in biologics and cell therapy markets.
6 members of Congress have disclosed 14 trades in Lonza Group AG (LZAGY), a Healthcare company. The buy/sell breakdown shows 5 purchases versus 9 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-12-21 | Josh Gottheimer | sell | $1K – $15K |
| 2023-12-05 | Josh Gottheimer | sell | $1K – $15K |
| 2023-07-10 | Daniel Goldman | sell | $15K – $50K |
| 2021-04-13 | Josh Gottheimer | sell | $1K – $15K |
| 2021-02-17 | Peter Meijer | sell | $15K – $50K |
| 2021-01-28 | Peter Meijer | sell | $1K – $15K |
| 2020-03-06 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2020-01-13 | Greg Gianforte | buy | $15K – $50K |
| 2019-12-10 | Greg Gianforte | sell | $50K – $100K |
| 2019-11-27 | Josh Gottheimer | sell | $1K – $15K |
| 2019-06-24 | Donna Shalala | sell | $1K – $15K |
| 2018-05-14 | Greg Gianforte | buy | $100K – $250K |
| 2018-05-09 | Josh Gottheimer | buy | $1K – $15K |
| 2018-05-08 | Josh Gottheimer | buy | $1K – $15K |